Please login to the form below

Not currently logged in
Email:
Password:

GSK partners with Singapore research agency on emerging markets

Will work with A*STAR’s Institute of Chemical and Engineering to research reformulated medicines

Will work with A*STAR's Institute of Chemical and Engineering to research reformulated medicines

GlaxoSmithKline (GSK) is to partner with Singapore's lead government agency for research to develop new formulations of existing medicines specifically for emerging markets.

The UK-based pharma company will work with the Agency for Science, Technology and Research's (A*STAR) Institute of Chemical and Engineering Sciences over the next five years to research reformulated medicines, taking advantage of a growing demand for pharmaceutical products in emerging markets, including China, Brazil, India and Russia.

It expands on an existing relationship between A*STAR and GSK that began in 2003 and includes a 2012 agreement with the Agency's Genome Institute of Singapore (GIS) to research treatments for lung cancer.

The latest deal for evidence-based formulations (EBFs) reinforces Singapore as both GSK's hub for emerging markets and an important base for the pharma industry, as companies look towards growth in nearby countries, including Indonesia, India and Vietnam.

Duncan McKay, VP, emerging markets & Asia Pacific R&D, GSK, said the agreement was part of the company's strategy of “growing a diversified global business”.

He said: “Within GSK's portfolio of off-patent products, EBFs are an important part of our growth strategy, and our hope is that together with the Institute of Chemical and Engineering Sciences, we will create a sustainable, scalable model to meet both specific market conditions and patient requirements.”

Kevin Lai, director of biomedical sciences for Singapore's Economic Development Board, gave the government perspective.

“This is a strong endorsement of Singapore's scientific talent and capabilities,” he said. “It also further reinforces Singapore's offering as the base for companies to generate insights and develop new solutions and market access strategies for the fast growing emerging markets.”

9th April 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics